Ocuphire Pharma Investor Presentation Deck
10
Secondary Endpoint: Mean Pupil Diameter Over Time
Achieved Pupil Size ~2mm in Nyxol+LDP Consistent with 3-line Improvement in Near Vision
Mean Pupil Diameter (mm)
5.0
4.0
3.0
2.0
1.0
4.8
4.4
4.3
4.2
***
Baseline
***
3.1
Daily Evening
Nyxol Dosing 12 hr
minimum interval to
Time 0
0
4.5 ***
4.3
3.2
***
**
16 4
4.5
3.2
3.0
2.4
*** T
***
**
1
4.4
3.2
2.5
2.1
VEGA-1 Phase 2 Trial
Best Eye
Mean Pupil Diameter
-Placebo (n=43)
***T
***1
**
4.3
3.4
2.7
2.3
***
***
***
4.4
3
3.3
3.1
2.5
2
Time (Hours)
-Nyxol+LDP (n=43) -Nyxol (n=30)
***
***
1
***
4.4
3.3
3.3
2.7
Nyxol+LDP arm
statistically significant
compared to all arms
-LDP (n=31)
Source: VEGA-1 TLR Table 14.2.12.1 Observed Values and Change from Baseline in Photopic Pupil Diameter by Time Point (PP Population)
**p<0.01
***p<0.0001
5
***
4.6
6
3.6
** 3.3
2.9
Ocuphire
PHARMAView entire presentation